164 related articles for article (PubMed ID: 35876661)
1. Non-steroidal anti-inflammatory drugs and risk of myocardial infarction adjusting for use of proton pump-inhibitors in patients with no major risk factors: a nested case-control study in the UK Clinical Practice Research Datalink.
Baak BN; Jick SS
Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):58-75. PubMed ID: 35876661
[TBL] [Abstract][Full Text] [Related]
2. Proton-pump Inhibitor Use and Myocardial Infarction: A Nested Case-Control Study in the UK Clinical Practice Research Datalink.
Qian Y; Jick S
Epidemiology; 2020 May; 31(3):423-431. PubMed ID: 31809341
[TBL] [Abstract][Full Text] [Related]
3. Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?
van Staa TP; Rietbrock S; Setakis E; Leufkens HG
J Intern Med; 2008 Nov; 264(5):481-92. PubMed ID: 18624902
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study.
Schmidt M; Hallas J; Ernst MT; Pottegård A
Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):562-569. PubMed ID: 37385823
[TBL] [Abstract][Full Text] [Related]
5. Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis.
Dubreuil M; Louie-Gao Q; Peloquin CE; Choi HK; Zhang Y; Neogi T
Ann Rheum Dis; 2018 Aug; 77(8):1137-1142. PubMed ID: 29674321
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPI) on hospitalisation due to peptic ulcer disease.
Höer A; Gothe H; Schiffhorst G; Sterzel A; Grass U; Häussler B
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):854-8. PubMed ID: 17323403
[TBL] [Abstract][Full Text] [Related]
7. Impact of proton pump inhibitor treatment on gastrointestinal bleeding associated with non-steroidal anti-inflammatory drug use among post-myocardial infarction patients taking antithrombotics: nationwide study.
Schjerning Olsen AM; Lindhardsen J; Gislason GH; McGettigan P; Hlatky MA; Fosbøl E; Køber L; Torp-Pedersen C; Lamberts M
BMJ; 2015 Oct; 351():h5096. PubMed ID: 26481405
[TBL] [Abstract][Full Text] [Related]
8. Meloxicam and risk of myocardial infarction: a population-based nested case-control study.
Dalal D; Dubreuil M; Peloquin C; Neogi T; Zhang Y; Choi H; Felson D
Rheumatol Int; 2017 Dec; 37(12):2071-2078. PubMed ID: 29030657
[TBL] [Abstract][Full Text] [Related]
9. Use of non-steroidal anti-inflammatory drugs correlates with the risk of venous thromboembolism in knee osteoarthritis patients: a UK population-based case-control study.
Lee T; Lu N; Felson DT; Choi HK; Dalal DS; Zhang Y; Dubreuil M
Rheumatology (Oxford); 2016 Jun; 55(6):1099-105. PubMed ID: 26983451
[TBL] [Abstract][Full Text] [Related]
10. Risk of acute myocardial infarction with real-world NSAIDs depends on dose and timing of exposure.
Bally M; Beauchamp ME; Abrahamowicz M; Nadeau L; Brophy JM
Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):69-77. PubMed ID: 29171096
[TBL] [Abstract][Full Text] [Related]
11. Risk of ST versus non-ST elevation myocardial infarction associated with non-steroidal anti-inflammatory drugs.
Grimaldi-Bensouda L; Rossignol M; Danchin N; Steg PG; Bessede G; Ovize M; Cottin Y; Autret-Leca E; Benichou J; Abenhaim L;
Heart; 2011 Nov; 97(22):1834-40. PubMed ID: 21880652
[TBL] [Abstract][Full Text] [Related]
12. Diclofenac and acute myocardial infarction in patients with no major risk factors.
Jick SS; Kaye JA; Jick H
Br J Clin Pharmacol; 2007 Nov; 64(5):662-7. PubMed ID: 17509036
[TBL] [Abstract][Full Text] [Related]
13. Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: analysis of a large United States claims database.
Schnitzer TJ; Kong SX; Mavros PP; Straus WL; Watson DJ
Clin Ther; 2001 Dec; 23(12):1984-98. PubMed ID: 11813933
[TBL] [Abstract][Full Text] [Related]
14. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
Kimmel SE; Berlin JA; Reilly M; Jaskowiak J; Kishel L; Chittams J; Strom BL
Ann Intern Med; 2005 Feb; 142(3):157-64. PubMed ID: 15684203
[TBL] [Abstract][Full Text] [Related]
15. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.
Hippisley-Cox J; Coupland C
BMJ; 2005 Jun; 330(7504):1366. PubMed ID: 15947398
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
[TBL] [Abstract][Full Text] [Related]
17. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study.
Schjerning Olsen AM; Fosbøl EL; Lindhardsen J; Folke F; Charlot M; Selmer C; Lamberts M; Bjerring Olesen J; Køber L; Hansen PR; Torp-Pedersen C; Gislason GH
Circulation; 2011 May; 123(20):2226-35. PubMed ID: 21555710
[TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitor use represents an independent risk factor for myocardial infarction.
Shih CJ; Chen YT; Ou SM; Li SY; Chen TJ; Wang SJ
Int J Cardiol; 2014 Nov; 177(1):292-7. PubMed ID: 25499395
[TBL] [Abstract][Full Text] [Related]
19. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction.
Hernández-Díaz S; Varas-Lorenzo C; García Rodríguez LA
Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):266-74. PubMed ID: 16611201
[TBL] [Abstract][Full Text] [Related]
20. Nonsteroidal antiinflammatory drugs and acute myocardial infarction in patients with no major risk factors.
Jick H; Kaye JA; Russmann S; Jick SS
Pharmacotherapy; 2006 Oct; 26(10):1379-87. PubMed ID: 16999647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
